Flagship record · Pramlintide

Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.

reviewnarrative reviewclass level evidence

Scientific attribution

The source reviews amylin physiology and therapeutic development at the amylin-class level rather than pramlintide as a primary intervention.

PMID: 38338796
DOI: 10.3390/ijms25031517
Sample size: Not captured in the structured review record
Population / model: Since the majority of type 2 diabetes mellitus patients are overweight or obese, a novel term-diabesity-has emerged.

Outcomes

Aside from its effect on glucose homeostasis, amylin inhibits homeostatic and hedonic feeding, induces satiety, and decreases body weight.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.